Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.

de Jong MA, Petrykiv SI, Laverman GD, van Herwaarden AE, de Zeeuw D, Bakker SJL, Heerspink HJL, de Borst MH.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):66-73. doi: 10.2215/CJN.04530418. Epub 2018 Dec 17.

PMID:
30559106
2.

Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.

Petrykiv SI, Laverman GD, Persson F, Vogt L, Rossing P, de Borst MH, Gansevoort RT, de Zeeuw D, Heerspink HJL.

Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1804-1813. doi: 10.2215/CJN.00390117. Epub 2017 Oct 11. Review.

3.

The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.

Petrykiv SI, Laverman GD, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2017 Oct;19(10):1363-1370. doi: 10.1111/dom.12936. Epub 2017 Jun 8.

PMID:
28295959
4.

Variability in response to albuminuria-lowering drugs: true or random?

Petrykiv SI, de Zeeuw D, Persson F, Rossing P, Gansevoort RT, Laverman GD, Heerspink HJL.

Br J Clin Pharmacol. 2017 Jun;83(6):1197-1204. doi: 10.1111/bcp.13217. Epub 2017 Feb 1.

Supplemental Content

Loading ...
Support Center